Scholarlink

<p>Platinum-based drugs exhibit potent anti-tumor efficacy but are limited by low bioavailability, severe toxicity, and resistance. Current therapeutic strategies lack effective solutions due to the unclear molecular mechanisms. Autophagy, with its dual protective/destructive roles, offers potential to enhance platinum-based chemotherapy, yet its clinical translation for optimizing therapeutic outcomes remains underexplored. To address this challenge, we screened a Natural Compounds Library (NCL) to identify low-toxicity agents that synergize with Cisplatin (Cis). Among 285 autophagy-related candidates, Catharanthine (CA) emerged as a specific autophagy activator model molecule that reduced toxicity and synergistically suppressed gastric cancer (GC) when combined with Cis. Mechanistically, CA promoted organ protection via endoplasmic reticulum stress (ERS)/AMPKα-dependent autophagy activation. The CA-Cis combination induced tumor-suppressive effects, including ERS, autophagosome accumulation, and cytoskeletal impairment in cancer cells. Conversely, CA-mediated autophagy protected normal cells, as AMPKα knockdown abolished this protection, resulting in DNA damage and apoptosis. These results highlight the dual autophagic flux regulation: tumor cells undergo destructive autophagy, while normal cells experience protective autophagy, establishing a favorable therapeutic balance. We confirmed that the CA-Cis combination activates autophagy through the AMPKα-ULK1 pathway in both tumor and non-tumor tissues and differentially regulates phosphorylation at serine 757 of ULK1, this differentiation can dramatically modulate autophagy activity, thereby mediating context-dependent dual outcomes of autophagic protection and detrimental effects. These findings elucidate a mechanism whereby CA enhances platinum efficacy by remodeling of autophagic homeostasis in organisms, providing a theoretical basis for optimizing platinum-based regimens. Our study bridges autophagy’s dual functionality with clinical strategy, proposing the combination of specific autophagy activators as a promising approach to overcome platinum resistance and toxicity in GC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Guangzhao Pan,
  • Qianqian Xu,
  • Kui Zhang,
  • Xin Hu,
  • Chongyang Li,
  • Changhong Li,
  • Haoyan Ji,
  • Xiaosong Hu,
  • Shaomin Shi,
  • Renjian Hu,
  • Chaowei Deng,
  • Erhu Zhao,
  • Jinfei Chen,
  • Hongjuan Cui

摘要

Platinum-based drugs exhibit potent anti-tumor efficacy but are limited by low bioavailability, severe toxicity, and resistance. Current therapeutic strategies lack effective solutions due to the unclear molecular mechanisms. Autophagy, with its dual protective/destructive roles, offers potential to enhance platinum-based chemotherapy, yet its clinical translation for optimizing therapeutic outcomes remains underexplored. To address this challenge, we screened a Natural Compounds Library (NCL) to identify low-toxicity agents that synergize with Cisplatin (Cis). Among 285 autophagy-related candidates, Catharanthine (CA) emerged as a specific autophagy activator model molecule that reduced toxicity and synergistically suppressed gastric cancer (GC) when combined with Cis. Mechanistically, CA promoted organ protection via endoplasmic reticulum stress (ERS)/AMPKα-dependent autophagy activation. The CA-Cis combination induced tumor-suppressive effects, including ERS, autophagosome accumulation, and cytoskeletal impairment in cancer cells. Conversely, CA-mediated autophagy protected normal cells, as AMPKα knockdown abolished this protection, resulting in DNA damage and apoptosis. These results highlight the dual autophagic flux regulation: tumor cells undergo destructive autophagy, while normal cells experience protective autophagy, establishing a favorable therapeutic balance. We confirmed that the CA-Cis combination activates autophagy through the AMPKα-ULK1 pathway in both tumor and non-tumor tissues and differentially regulates phosphorylation at serine 757 of ULK1, this differentiation can dramatically modulate autophagy activity, thereby mediating context-dependent dual outcomes of autophagic protection and detrimental effects. These findings elucidate a mechanism whereby CA enhances platinum efficacy by remodeling of autophagic homeostasis in organisms, providing a theoretical basis for optimizing platinum-based regimens. Our study bridges autophagy’s dual functionality with clinical strategy, proposing the combination of specific autophagy activators as a promising approach to overcome platinum resistance and toxicity in GC treatment.